Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II neoadjuvant study of EC followed by docetaxel plus trastuzumab versus docetaxel plus lapatinib in HER2-positive breast cancer
2007-007031-13Phase 2Active
- Sponsor
- GEICAM
- Start
- Oct 2008
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lapatinib, trastuzumab, epirubicin, cyclophosphamide and docetaxel in breast cancer (2 arms), sponsored by GEICAM. Primary endpoint: Pathological complete response rate. Started Oct 2008; status: active.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2007-007031-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-007031-13.